Ångström AI
Gen AI molecular simulations that reproduce wetlab results
What they do
Pre-clinical drug development relies on slow, expensive wet lab experiments to test drug candidate efficacy and safety.
They provide physics-constrained generative AI molecular simulations that reproduce wet lab results much faster than experiments.
Biotech and pharmaceutical R&D teams developing new drug candidates in the pre-clinical pipeline.
Founders
Miguel is co-founder of Ångström AI and Professor of Machine Learning at the Department of Engineering, University of Cambridge, UK. He has nearly 20 years of research experience in Machine Learning and his work has been cited over 15,000 times. His research in Machine Learning for Molecules has led him to build strong relationships with partners in BioTech and Pharma. Before joining Cambridge as a faculty, he was a postdoctoral fellow at Harvard University.
I'm the co-founder of Ångström AI which substitutes wet lab experiments with physically accurate GenAI molecular simulations for clients in Pharma and BioTech. Before founding Ångström AI, I was a research engineer at InstaDeep (acquired by BioNTech 2023), and pursued a PhD at the University of Cambridge in generative AI models for molecular systems. I love coding and surfing, reach out if you are in the Bay Area and want to catch some waves.
Company timeline
- Founded2024
- YC batchSummer 2024
- StatusActive
- Team size5 people
- LocationSan Francisco, CA, USA
Similar startups
